Sun et al. fabricated US-responsive MBs consisting of camptothecin (CPT)−floxuridine (FUDR) (CF) conjugate and anti-PD-L1 (αPFC MBs) in order to achieve higher tumor cell uptake and deeper tumor penetration (Sun et al., 2022) (Figure 1D). This evidence concerns the gene CD274 and neoplasm.